Navigation path

Healthcare Industries

Reference documents

The objective of the work of Directorate-General for Enterprise and Industry in the healthcare industries sector is to develop and maintain a favourable environment for medicinal products in the European Union which guarantees a high level of protection of public health, contributes to the completion of the Single Market in pharmaceuticals and fosters a stable and predictable environment for pharmaceutical innovation and competitiveness.

This section provides links to the following:

  • Communication on the future of the Pharmaceutical sector

    On 10 December 2008, the European Commission adopted a communication on the future of the pharmaceutical sector as part of the pharmaceutical package. The Communication sets out a vision for the future of the pharmaceutical sector, addresses the main challenges that lie ahead and proposes concrete deliverables for the years to come.
  • The volumes of "The rules governing medicinal products in the European Union" (EUDRALEX) which contain all Community legislation in the areas of medicinal products for human and veterinary use.
  • The Community Register which is a register that contains a listing of all medicinal products for human and veterinary use, as well as orphan medicinal products, that have received a marketing authorisation through the centralised procedure.
  • The reports of the Pharmaceutical Committee , which is an advisory Committee made of senior experts from the Member States, entrusted with the task of examining all questions relating to proprietary medicinal products, and in particular, the preparation of proposals for Directives.
  • A listing of the judgements of the European Court of Justice of particular interest for the pharmaceutical sector.
  • The news archives which include all major news related to pharmaceuticals published in the past on this website.
  • High-Level Group on Innovation and the Provision of Medicines : G10 Medicines - Report 2002
    The G10 Group was assigned to explore different ways to enhance pharmaceutical industry competitiveness in Europe. The G10 report , issued in 2002, contains a total of fourteen wide-ranging recommendations. In response to the G10 report, the European Commission adopted on 1 July 2003 the Communication "A stronger European-based pharmaceutical industry for the benefit of the patient - a call for action" pdf български (bg) czech (cs) dansk (da) Deutsch (de) eesti (et) ελληνικά (el) español (es) Français (fr) Gaeilge (ga) hrvatski (hr) italiano (it) latviešu (lv) lietuvių (lt) magyar (hu) Malti (mt) Nederlands (nl) polski (pl) português (pt) română (ro) slovenčina (sk) slovenščina (sl) suomi (fi) svenska (sv) [360 KB] which outlines the Commission's proposals to advance the G10 recommendations.
  • The Pharmaceutical Forum  was set up in 2005 as a three-year process by Vice-President Verheugen and former Commissioner Kyprianou, in order to find relevant solutions to public health considerations regarding pharmaceuticals, while ensuring the competitiveness of the industry and the sustainability of the national healthcare systems.
    Pharmaceutical Forum 2005-2008: Conclusions and Recommendations
  • Transparency Directive 89/105/EEC lays down harmonised provisions to ensure the transparency of national provisions regulating the pricing and reimbursement of medicinal products. It is commonly referred to as the "Transparency Directive" and was adopted at the end of the 1980s.

Share: FacebookGoogle+LinkedInsend this page to a friend

Set page to normal font sizeIncrease font size by 200 percentprint this page